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Abstract
Background: The co-morbidity of health conditions is becoming a significant health issue, particularly as
populations age, and presents important methodological challenges for population health research. For
example, the calculation of summary measures of population health (SMPH) can be compromised if co-
morbidity is not taken into account. One popular co-morbidity adjustment used in SMPH computations
relies on a straightforward multiplicative combination of the severity weights for the individual conditions
involved. While the convenience and simplicity of the multiplicative model are attractive, its
appropriateness has yet to be formally tested. The primary objective of the current study was therefore
to examine the empirical evidence in support of this approach.
Methods: The present study drew on information on the prevalence of chronic conditions and a utility-
based measure of health-related quality of life (HRQoL), namely the Health Utilities Index Mark 3 (HUI3),
available from Cycle 1.1 of the Canadian Community Health Survey (CCHS; 2000–01). Average HUI3
scores were computed for both single and co-morbid conditions, and were also purified by statistically
removing the loss of functional health due to health problems other than the chronic conditions reported.
The co-morbidity rule was specified as a multiplicative combination of the purified average observed HUI3
utility scores for the individual conditions involved, with the addition of a synergy coefficient s for capturing
any interaction between the conditions not explained by the product of their utilities. The fit of the model
to the purified average observed utilities for the co-morbid conditions was optimized using ordinary least
squares regression to estimate s. Replicability of the results was assessed by applying the method to triple
co-morbidities from the CCHS cycle 1.1 database, as well as to double and triple co-morbidities from cycle
2.1 of the CCHS (2003–04).
Results: Model fit was optimized at s = .99 (i.e., essentially a straightforward multiplicative model). These
results were closely replicated with triple co-morbidities reported on CCHS 2000–01, as well as with
double and triple co-morbidities reported on CCHS 2003–04.
Conclusion: The findings support the simple multiplicative model for computing utilities for co-morbid
conditions from the utilities for the individual conditions involved. Future work using a wider variety of
conditions and data sources could serve to further evaluate and refine the approach.
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Background
Over the past century, advances in both public and popu-
lation health have dramatically increased life expectancy
in many parts of the developed world. However, these
improvements in life expectancy may be accompanied by
higher morbidity due to the increased presence of chronic
conditions. Indeed, the phenomenon of co-morbidity –
the clustering of different health conditions within indi-
viduals – is quite common as populations age [1,2]. A
substantial amount of empirical research has shown that
the number of co-morbid conditions experienced by
patients is positively associated with mortality risk, utili-
zation of health care services, and decrements in health-
related quality of life (HRQoL) [3,4]. Given this consider-
able economic and HRQoL impact of co-morbidity, and
also that the proportion of those aged 65 and over is
expected to increase substantially in many developed
countries over the next two decades [5], it is not surprising
that co-morbidity has been identified as a key research pri-
ority by a number of researchers [3,6]. For those examin-
ing this issue, quantitative methods for handling co-
morbidity are essential, in order to avoid bias when gen-
erating various indices of the impact of chronic and other
conditions [7].
Adjusting for co-morbidity is particularly important in the
computation of summary measures of population health
(SMPH) that combine information on mortality and mor-
bidity [8]. Over the past 15 years, there has been a steady
increase in methodological sophistication for dealing
with co-morbidity in SMPH calculations. In the original
Global Burden of Disease (GBD) study conducted by the
World Health Organization (WHO) and its collaborators
in 1990, co-morbidity resulted in overestimation of total
disability-adjusted life years (DALYs), since the severity-
weighted prevalence of various specific conditions was
simply summed as part of the overall burden calculation
[9]. Researchers in the Netherlands also adopted this
methodology [10]. However, Murray and Lopez have
since acknowledged that the additive approach to co-mor-
bidity used in the GBD 1990 was overly simplistic and
implausible [11].
Recognizing such issues, an alternative approach was
undertaken for the DALY calculations in the Australian
[12] and Victorian [13] Burden of Disease studies. Specif-
ically, in order to adjust for the co-morbidity of prevalent
mild conditions in older age groups, the severity weights
for the individual conditions were combined a priori using
a multiplicative model. Given its simplicity and ease of
interpretation, the multiplicative "rule" for combining
severity weights for individual conditions continues to be
used when adjusting SMPH for co-morbidity [14-16];
however, its appropriateness has not yet been verified
empirically. Mathers et al. [17] concluded that until
research directly addresses how severity weights should be
combined, the multiplicative approach appears reasona-
ble. However, as Schneeweis et al. [18] have noted, there
currently exists no "gold standard" method or measure for
dealing with co-morbidity, with most being selected for
"convenience rather than performance." Therefore, it is
important to subject the co-morbidity methods that have
been proposed to more rigorous empirical testing, in
order to better determine their effectiveness and identify
areas for potential refinement. Such an approach will
assist in improving ongoing efforts to develop SMPH
attributable to individual conditions [19]; in particular, it
would contribute to a more precise rank ordering of con-
ditions in terms of their population health impact,
thereby better informing health policy decisions concern-
ing the allocation of scarce societal resources to preven-
tion and treatment programs.
With these considerations in mind, the present study spe-
cifically tested the extent to which a multiplicative model
for combining the health state utilities for individual con-
ditions could reproduce the utility for the co-morbidity of
the same conditions (see Appendix A, Note 1). To meet
this objective, this study used self-reported information
on both HRQoL and the prevalence of chronic conditions
in Canada from a nationally representative population
health survey.
Methods
Functional form of the co-morbidity rule
In its simplest form, a multiplicative model for combining
the utilities of two or more distinct conditions u1 and u2 to
generate a theoretical utility  1,2 for their co-morbidity is
written as follows:
1,2 = u1 * u2   [1]
Such a model has three desirable properties. First, for
health utilities between 0 (death) and 1 (full health), their
product is also bounded by 0 and 1. A second and intui-
tively appealing property of the model is that the utility
for the co-morbidity is proportional to the individual util-
ities associated with each of the individual conditions
involved. In other words, each additional condition
reduces functional health relative to its previous level. For
example, those in full health who developed a condition
having an associated utility of 0.90 would maintain 90%
of full functional health, that is, a utility of 0.90. If they
developed a second condition with utility 0.80, their util-
ity for their functional health state would be reduced to
0.72 (i.e., .80 * .90). Third, a multiplicative model can be
applied to the utilities for any number of conditions, and
is commutative.
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Since the purpose of the present study is to assess the
appropriateness of the multiplicative model by examining
how well it could reproduce observed utilities associated
with co-morbid conditions, it is necessary to augment
Equation [1] with a "synergy" coefficient s, as follows:
1,2 = s * (u1 * u2 ).   [2]
The inclusion of s in the formula allows the model to be
adjusted to better fit the data; and therefore the value esti-
mated for s can be used to judge the appropriateness of the
multiplicative form. In particular, a synergy coefficient
close to 1 would indicate that most of the utility associ-
ated with co-morbidity is explained by the straightforward
multiplication of the utilities for the separate conditions,
showing that the simple multiplicative form is appropri-
ate. On the other hand, a synergy coefficient far from 1
would indicate that most of the utility linked to co-mor-
bidity is explained by this coefficient. In this case, one
would conclude that there is additional interaction
among conditions not adequately accounted for by the
simple multiplicative model.
Data Source and Variables
To empirically evaluate the multiplicative model, it was
first necessary to obtain information on both chronic con-
dition prevalence and HRQoL, in order to link observed
health state utilities to both single and co-morbid chronic
conditions. This analysis used self-reported data on these
variables from cycle 1.1 of the Canadian Community
Health Survey (CCHS), conducted in 2000–01 [20]. The
CCHS is an ongoing, cross-sectional survey that collects
information on health status, health determinants, and
health care utilization. It is representative of the Canadian
household population aged 12 and over in all provinces
and territories, and excludes populations on Indian
Reserves, Canadian Forces Bases, and certain remote areas.
The sample size was 131,535 respondents in this first
cycle. In addition, in order to verify the findings obtained
with the cycle 1.1 data, we conducted a validation study
using cycle 2.1 of the CCHS, conducted in 2003–04. This
dataset contained 45,101 respondents who were asked
questions related to the analysis variables of interest here.
Regarding the distribution of chronic conditions in the
population, respondents to the CCHS cycle 1.1 were
asked to indicate if they had any of 27 specific chronic
conditions (Table 1), defined as "conditions that have
lasted or are expected to last six months or more and have
been diagnosed by a health professional." For the meas-
ure of HRQoL, the Health Utilities Index Mark 3 (HUI3)
was selected [21,22]. The HUI3 is a derived variable on
the CCHS database and is based on a respondent's stand-
ing on eight underlying health status attributes: Vision,
Hearing, Speech, Ambulation, Dexterity, Emotion, Cogni-
tion, and Pain. Each attribute has five to six levels ranging
from normal to severely limited functioning. For example,
the Ambulation attribute has levels which range from 1
("Able to walk around the neighbourhood without diffi-
culty, and without walking equipment") to 6 ("Unable to
walk at all"). On the CCHS, respondents were asked a
standardized set of questions on usual functional ability
or capacity, which map to the levels on the eight attributes
of the HUI3. Finally, the individual's scores across the
eight attributes were combined using the HUI3 multi-
attribute utility function in order to yield a global utility
score representing the HRQoL of the respondent [23].
This score has a theoretical range of -0.36 to 1, where -0.36
and 1 represent the utilities of the worst and best possible
HUI3 health states, respectively; and 0 represents death
[22].
Data preparation
All analyses were conducted using SAS version 9.1. Aver-
age HUI3 scores were computed for groups of persons
reporting no, one or two chronic conditions, and were
age- and sex-standardized to the Canadian population as
represented by the survey sample weights (see Appendix
A, Note 2) [24]. Further, to account for the complex sam-
pling design of the CCHS, survey bootstrap weights were
used to generate estimates of standard error (SE) around
the mean estimates [25,26]. For the calculation of the
average HUI3 associated with a pair of conditions, cases
were excluded if they had missing values for the HUI3
score, or "unstated/unknown/refused" recorded for the
chronic condition(s).
Purification of HUI3 scores
Prior to estimating the model, another data preparation
step involved purifying the average HUI3 scores in order to
better reflect the HRQoL impact of the chronic conditions
reported. A preliminary analysis revealed that the average
HUI3 score of persons reporting no chronic conditions
was less than full health: 0.94 (SE = 0.00). This may be
due to conditions other than those specifically surveyed,
such as influenza, or it may reflect a general state of health
associated with ageing and not associated with any spe-
cific condition. Therefore, we postulated that for persons
reporting one or more chronic conditions, part of their
HUI3 score may also be attributable to these other factors.
In other words, we have assumed that the derived HUI3
score on CCHS represented a co-morbidity of the condi-
tion(s) reported and these other factors. To avoid double-
counting such effects when applying a co-morbidity rule,
we purified all average HUI3 scores by removing the loss of
functional health associated with these other factors. Spe-
cifically, purification was achieved by dividing the average
HUI3 score for cases reporting one or more conditions by
the average HUI3 score for those reporting no conditions.
The resulting purified score is held to uniquely represent
ˆ uPopulation Health Metrics 2006, 4:13 http://www.pophealthmetrics.com/content/4/1/13
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the utility associated with a given condition or combina-
tion of conditions, free of potential confounding due to
additional unknown factors that impact functional
health.
Estimation of synergy coefficient s
The synergy coefficient that produced the best fit to the
data was determined by applying the co-morbidity rule
defined in Equation [2] across all co-morbid pairs of
chronic conditions reported on the CCHS cycle 1.1. First,
for each co-morbid pair, we computed a theoretical utility,
namely the product of the purified average observed utili-
ties for the individual conditions reported alone (see
Equation [1]). Second, in order to estimate s, these theo-
retical utilities were fitted to the purified average observed
utilities for the co-morbid pairs of chronic conditions,
using ordinary least squares regression. The analysis was
weighted according to the prevalence of the observed co-
morbidities.
Replicability
It is important to recognize that the optimal value
obtained for the synergy coefficient s in the initial analysis
might be sample-specific. Therefore, an additional objec-
tive was to determine the replicability of the results with
respect to more than two co-morbid conditions, as well as
in an independent data set. Thus, the co-morbidity rule
was also applied to the set of respondents reporting three
conditions on CCHS cycle 1.1, and to respondents report-
ing two and three chronic conditions on CCHS cycle 2.1.
Results
Descriptive statistics
The average age- and sex-standardized HUI3 score for per-
sons reporting no chronic conditions was 0.94 (SE =
0.00). Thus a loss of utility of 0.06 was assumed to be
associated with factors other than those reported by the
respondents, and was used to purify the average HUI3
scores of persons reporting one or more conditions. Per-
Table 1: Observed and purified HUI3 scores of 26 chronic conditions surveyed in cycle 1.1 of CCHS
Condition reported alone on CCHS ObservedΦ HUI3 Purified† HUI3
Non-Food Allergies 0.93 (0.00) 1.00 (0.00)
Thyroid Condition 0.93 (0.01) 1.00 (0.01)
Food Allergies 0.93 (0.01) 0.99 (0.01)
Cataracts 0.92 (0.01) 0.99 (0.01)
High Blood Pressure 0.92 (0.00) 0.98 (0.00)
Asthma 0.92 (0.01) 0.98 (0.01)
Suffers/Multiple Chemical Sensitivities 0.92 (0.02) 0.98 (0.02)
Diabetes 0.91 (0.01) 0.97 (0.01)
Heart Disease 0.90 (0.01) 0.97 (0.01)
Bowel Disorder-Crohn's Disease/Colitis 0.90 (0.01) 0.97 (0.01)
Migraine Headaches 0.90 (0.01) 0.97 (0.01)
Glaucoma 0.90 (0.02) 0.96 (0.03)
Stomach/Intestinal Ulcers 0.90 (0.01) 0.96 (0.01)
Chronic Bronchitis 0.89 (0.01) 0.96 (0.01)
Cancer 0.89 (0.02) 0.95 (0.02)
Epilepsy 0.88 (0.02) 0.94 (0.02)
Arthritis/Rheumatism 0.88 (0.01) 0.94 (0.01)
Back Problems* 0.88 (0.00) 0.94 (0.00)
Emphysema/COPD 0.87 (0.03) 0.93 (0.03)
Fibromyalgia 0.86 (0.02) 0.92 (0.02)
Chronic Fatigue Syndrome 0.81 (0.04) 0.87 (0.04)
Urinary Incontinence 0.76 (0.06) 0.81 (0.06)
Parkinson's Disease 0.75 (0.05) 0.80 (0.05)
Suffers From The Effects Of A Stroke 0.69 (0.08) 0.74 (0.08)
Multiple Sclerosis 0.69 (0.05) 0.74 (0.05)
Alzheimer's Disease/Other Dementia 0.45 (0.06) 0.48 (0.07)
Notes:
Conditions are shown in descending order of prevalence.
Standard error is shown in brackets following the estimate.
* Back problems excluding fibromyalgia & arthritis.
Φ Observed refers to the average, age-sex standardized HUI3 scores of the condition reported alone on CCHS before being purified.
† Purified refers to the average observed utility after division by the average utility of those reporting no conditions.Population Health Metrics 2006, 4:13 http://www.pophealthmetrics.com/content/4/1/13
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sons reporting one chronic condition had average age-
and sex-standardized HUI3 scores ranging from 0.45 (SE
= 0.06) to 0.93 (SE = 0.00); their purified HUI3 ranged
from 0.48 (SE = 0.07) to 1.00 (SE = 0.00) (see Table 1).
Persons that reported two chronic conditions in CCHS
2000–01, had average age- and sex-standardized HUI3
scores ranging from -0.01 (SE = 0.00) to 1.00 (SE = 0.00).
However, the majority of these co-morbid conditions
were relatively mild; specifically, of the 278 pairs of two
conditions reported together on CCHS, 184 had average
HUI3 scores above 0.80, and this accounted for 90% of
the prevalence of all persons reporting two chronic condi-
tions together.
Estimation of synergy coefficient s
The synergy coefficient was estimated at s = 0.99, t(1) =
474.16 (p < .0001); the purified average observed utilities
for the co-morbid pairs were very closely reproduced by
the model, R2 = 0.99, F(1, 277) = 224828, (p < .0001).
Thus, the final form of the general co-morbidity rule for
combining the utilities of two separate conditions to esti-
mate the utility of their co-morbidity was the simple mul-
tiplicative model in Equation [1]. Table 2 shows the
average observed HUI3, the purified HUI3, and the theo-
retical utility estimated from the multiplicative rule for the
20 most prevalent pairs of co-morbid conditions on the
CCHS.
Replicability
The co-morbidity rule was also tested for persons report-
ing three conditions (n = 924) on CCHS cycle 1.1: the syn-
ergy coefficient that best fit this dataset was s = 0.99. When
the rule was tested on the next wave of CCHS (cycle 2.1
conducted in 2003–04) for two conditions (n = 299) and
for three conditions (n  = 734), the synergy coefficient
yielding the best fit to the data was also s = 0.99 in both
cases.
Discussion and conclusions
The purpose of this study was to test a conventionally
used multiplicative model for computing utilities for co-
morbid conditions from the utilities for the individual
conditions involved. Using information on the distribu-
tion of chronic conditions from a nationally representa-
tive general population health survey (CCHS 2000–01,
cycle 1.1), as well as a reliable and well-validated utility-
based measure of HRQoL (HUI3), it was found that a
straightforward multiplicative model best suited the cal-
Table 2: Observed, purified and theoretical estimates of health utility for the 20 most prevalent co-morbid conditions (descending) in 
cycle 1.1 of CCHS
Two conditions 
reported together on 
CCHS
ObservedΦ HUI3 Purified† HUI3 Theoretical‡ utility
Non-Food Allergies Asthma 0.93 (0.01) 1.00 (0.01) 0.98 (0.01)
Non-Food Allergies Back Problems* 0.86 (0.01) 0.92 (0.01) 0.94 (0.01)
Food Allergies Non-Food Allergies 0.92 (0.01) 0.99 (0.01) 0.99 (0.01)
Arthritis/Rheumatism Back Problems* 0.78 (0.01) 0.83 (0.01) 0.88 (0.01)
Non-Food Allergies Migraine Headaches 0.91 (0.01) 0.98 (0.01) 0.97 (0.01)
Arthritis/Rheumatism High Blood Pressure 0.85 (0.01) 0.91 (0.01) 0.93 (0.01)
Non-Food Allergies Arthritis/Rheumatism 0.83 (0.02) 0.89 (0.02) 0.94 (0.01)
Back Problems* Migraine Headaches 0.82 (0.01) 0.88 (0.01) 0.91 (0.01)
Non-Food Allergies High Blood Pressure 0.92 (0.01) 0.98 (0.01) 0.98 (0.01)
Back Problems* High Blood Pressure 0.86 (0.02) 0.92 (0.02) 0.92 (0.01)
High Blood Pressure Diabetes 0.89 (0.02) 0.96 (0.02) 0.96 (0.01)
Non-Food Allergies Thyroid Condition 0.92 (0.01) 0.99 (0.01) 1.00 (0.01)
High Blood Pressure Heart Disease 0.91 (0.02) 0.97 (0.02) 0.95 (0.01)
Arthritis/Rheumatism Migraine Headaches 0.84 (0.02) 0.90 (0.02) 0.91 (0.01)
Food Allergies Back Problems* 0.88 (0.01) 0.94 (0.01) 0.93 (0.01)
Asthma Back Problems* 0.87 (0.02) 0.93 (0.02) 0.92 (0.01)
High Blood Pressure Migraine Headaches 0.84 (0.02) 0.90 (0.02) 0.95 (0.01)
Food Allergies Asthma 0.92 (0.01) 0.98 (0.02) 0.97 (0.01)
Arthritis/Rheumatism Thyroid Condition 0.90 (0.02) 0.96 (0.02) 0.94 (0.01)
Food Allergies Migraine Headaches 0.91 (0.01) 0.98 (0.02) 0.96 (0.01)
Notes:
Standard error is shown in brackets following the estimate.
Conditions are shown in descending order of prevalence of the observed co-morbidity.
* Back problems excluding fibromyalgia & arthritis.
Φ Observed refers to the average, age-sex standardized HUI3 of the pair of conditions reported together on CCHS before being purified.
† Purified refers to the average observed utility after division by the average utility of those reporting no conditions.
‡ Theoretical refers to the utility estimated from the multiplicative rule (no synergy), using the purified HUI3 of the two conditions reported alone 
(Table 1).Population Health Metrics 2006, 4:13 http://www.pophealthmetrics.com/content/4/1/13
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culation of average utilities for 278 pairs of co-morbid
conditions. Specifically, a synergy coefficient s, applied to
the straightforward multiplicative model in order to allow
best fit to the data, optimized model fit at a value of 0.99.
This result shows that the utility linked to co-morbidity is
adequately explained via simple multiplication of the util-
ities for the individual conditions; in other words, there
appears to be no synergistic effect of having two or more
conditions. Further, these results were closely replicated
with respect to three co-morbid conditions and in an
independent sample of data from the CCHS 2003–04
(cycle 2.1), suggesting that the initial synergy coefficient
estimate was reliable and not just a sample-specific result
or an artifact of the survey methodology. This study is the
first to provide empirical confirmation of the multiplica-
tive model commonly used to adjust for co-morbidity in
the computation of SMPH [12-14,17].
The current support for this convenient and generalizable
co-morbidity rule is particularly encouraging, given that
other proposed methods for obtaining weights for co-
morbid conditions might be practically difficult to imple-
ment. With regard to the original GBD 1990 project, Mur-
ray [27] had suggested that another potentially viable
strategy for dealing with co-morbidity in future work
might be to generate unique weights for particular condi-
tion combinations, using further health state valuation
exercises (i.e., elicit the weights for co-morbidities directly
from panels of raters). Andrews and his colleagues [28]
also support this approach and note that empirical
research on co-morbidities could add important informa-
tion to the case descriptions used for the valuation exer-
cises. This particular strategy has not yet been
implemented, however, likely due to the considerable
resources required to perform valuations of all possible
co-morbidities. Further, any co-morbidities not consid-
ered in the initial valuation exercises, yet deemed relevant
in later studies, would necessitate assembling further val-
uation panels to obtain the weights. This study suggests
that the more easily-applied multiplicative model for
individual condition weights is reasonable for deriving
co-morbid condition weights in burden of disease
research.
A methodological strength of the present study is the puri-
fication strategy applied to the average observed HUI3
utilities for the single and co-morbid conditions. By
removing the loss of functional health attributable to
unknown factors, this approach helps provide a clearer
picture of the actual HRQoL impact of the conditions
studied. We therefore recommend using this approach in
similar future work, in order to minimize bias when using
utility measures to estimate the HRQoL consequences of
different conditions.
Some limitations of the current study should also be
noted. First, while the multiplicative co-morbidity rule
performs well in the prediction of average utilities, it is not
intended to be a predictor of individual outcomes (e.g.,
for a particular patient). However, within the area of
SMPH, the use of averages is appropriate. Second, the
majority of chronic conditions available for analysis from
the CCHS were relatively mild, that is, most of them do
not have a very large impact on functional health in terms
of HUI3 scores. Thus it is not certain that the co-morbidity
rule would hold with more severe combinations of condi-
tions such as might be found within clinical and institu-
tional populations, which are currently not part of the
CCHS. To address this issue, future evaluations of the co-
morbidity rule could utilize other information sources
such as hospital administrative databases. A related point
is that the prevalence estimates for chronic conditions
were self-rather than clinician-reported on the CCHS.
Thus it is possible that prevalence may have been under-
estimated and that the influence of unreported conditions
on functional health may have affected estimates of the
HUI3 utilities for the conditions studied [29,30]; how-
ever, the purification strategy used here may have offered
some protection against this problem. Again, future work
using clinical administrative databases might help rectify
such issues.
Despite these limitations, this study makes an important
contribution in that it provides the first empirical assess-
ment of the multiplicative rule for producing co-morbid
condition weights, and suggests that continued use of the
model is reasonable for use in constructing SMPH. Future
research incorporating some of the suggestions noted
above would serve to further evaluate and refine the
approach.
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Appendix A
Note 1: Utilities versus severity weights
A brief note of clarification is in order here. In the original
GBD 1990 study and the Australian and Victorian ver-
sions, the impact on HRQoL of a given disease was repre-
sented by a "severity weight" ranging between 0 (full
health) and 1 (death). In the current study, we quantify
HRQoL in terms of health state utilities, which are essen-
tially the complement of severity weights (i.e., 1 – severity
weight). The reason for this approach is to maintain con-
sistency with the HRQoL instrumentation used in the cur-
rent study, namely the Health Utilities Index Mark 3
(HUI3), which represents HRQoL as utilities.
Note 2: Method of age- and sex-standardization
All estimates of the average of the observed HUI3 utility
scores for each subpopulation, defined by the type of
chronic condition(s) reported, were age- and sex-stand-
ardized to the total Canadian population (age groups
were 12–19, 20–29, 30–39, 40–49, 50–59, 60–69, 70–79,
and 80+). This was accomplished in two main steps, as
follows:
(1) the CCHS survey sample weights were re-scaled
according to the ratio of the proportion of individuals in
the total Canadian population in a specific age group and
sex to the proportion of individuals in the subpopulation
having the chronic condition(s) in the same age group
and sex. This can be stated more formally:
vi,b = wi,b * pa,s /ya,s,b 
where
￿ vi,b represents the age- and sex-standardized survey sam-
ple weight of the ith record in the chronic condition sub-
population b (unitary or co-morbid);
￿ wi,b represents the survey sample weight of the ith record
in the chronic condition subpopulation b;
￿ pa,s represents the proportion of cases in the total Cana-
dian population in age group a of sex s, and is defined as
where wm is the survey sample weight for the mth of M
records in age group a with sex s, and wn is the survey sam-
ple weight for the nth of all N records in the entire CCHS
survey data file;
￿ ya,s,b , represents the proportion of cases in age group a
with sex s in the subpopulation b that have the chronic
condition(s), and is defined exactly like pa,s  except
restricted to cases in the subpopulation b, that is:
where wq is the survey sample weight for the qth of Q sur-
vey records in chronic condition subpopulation b in age
group a with sex s, and wr is the survey sample weight for
the rth of all R survey records in the chronic condition sub-
population b.
(2) the individual HUI3 utility scores of persons reporting
chronic condition(s) b were adjusted according to the age-
and sex-standardized weights from step 1, to estimate
average age- and sex-standardized HUI3 scores for each
chronic condition,  b , as follows:
where
￿ ui, b represents the observed HUI3 utility score for the ith
individual reporting chronic condition(s) b; and
￿ vi,b is defined as described in the first step above
Note that the average theoretical HUI3 scores were age-
standardized to the total Canadian population in the
same manner, assuming that the population of theoretical
co-morbid cases had the same age-sex structure as that of
their observed counterparts.
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